Drug Trial Radar · NCT04278131
BS01 in Patients With Retinitis Pigmentosa
Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Feb 6, 2020
Primary completion
Dec 30, 2026
Study completion Dec 30, 2029
Sponsor
- Lead sponsor
- Bionic Sight LLCIndustry
- Sponsor type
- Industry
- First posted
- Feb 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
Conditions
- Retinitis Pigmentosa
Interventions
BS01Drug
Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Outcome MeasureTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Jersey Retina
Teaneck, New Jersey · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.